Screener
Twist Bioscience Corporation TWST Reportable Segment — Stock-based compensation expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Twist Bioscience Corporation in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001581280-26-000040
| (in thousands) | Three months ended March 31, 2026 | Three months ended March 31, 2025 | Six months ended March 31, 2026 | Six months ended March 31, 2025 |
|---|---|---|---|---|
| Selling, general and administrative expenses[1] | 59,255 | 47,298 | 117,034 | 93,786 |
| Litigation settlement costs, net of recoveries | 7,205 | — | 7,205 | — |
| Depreciation and amortization | 6,414 | 6,402 | 12,608 | 12,784 |
| Stock-based compensation expense | 18,936 | 20,328 | 32,209 | 32,319 |
| Total costs and expenses | $156,578 | $134,353 | $293,176 | $257,711 |
| Loss from operations | $(45,863) | $(41,560) | $(78,763) | $(76,205) |
| Interest income | $1,710 | $2,801 | $3,885 | $6,041 |
| Other income (expense), net | 175 | (394) | 646 | (487) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Twist Bioscience Corporation's reportable segment — stock-based compensation expense?
- Twist Bioscience Corporation (TWST) reported reportable segment — stock-based compensation expense of $18.94M in Q1 2026.
- How has Twist Bioscience Corporation's reportable segment — stock-based compensation expense changed year-over-year?
- Twist Bioscience Corporation's reportable segment — stock-based compensation expense decreased by 6.8% year-over-year, from $20.33M to $18.94M.
- What does reportable segment — stock-based compensation expense mean?
- Measures the non-cash expense recognized for equity-based awards granted to employees and management within the reportable segment. It is a key indicator of talent retention costs and the dilution impact on existing shareholders.
Ask your AI about Twist Bioscience Corporation's reportable segment — stock-based compensation expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude